Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.

Tatsuaki TakedaHiromasa YamamotoHirotaka KanzakiKen SuzawaTakahiro YoshiokaShuta TomidaXiaojiang CuiRamachandran MuraliKei NambaHiroki SatoHidejiro TorigoeMototsugu WatanabeKazuhiko ShienJunichi SohHiroaki AsanoKazunori TsukudaYoshihisa KitamuraShinichiro MiyoshiToshiaki SendoShinichi Toyooka

Published in: PloS one (2017)

Yes1 plays an important role in acquired resistance to trastuzumab and lapatinib in HER2-positive breast cancer. Our data suggest that pharmacological inhibition of Yes1 may be an effective strategy to overcome resistance to trastuzumab and lapatinib.

Keyphrases

positive breast cancer
metastatic breast cancer
epidermal growth factor receptor
big data
deep learning
artificial intelligence
data analysis